These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 33685469)
1. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469 [TBL] [Abstract][Full Text] [Related]
2. Cholesteryl oleate-loaded cationic solid lipid nanoparticles as carriers for efficient gene-silencing therapy. Suñé-Pou M; Prieto-Sánchez S; El Yousfi Y; Boyero-Corral S; Nardi-Ricart A; Nofrerias-Roig I; Pérez-Lozano P; García-Montoya E; Miñarro-Carmona M; Ticó JR; Suñé-Negre JM; Hernández-Munain C; Suñé C Int J Nanomedicine; 2018; 13():3223-3233. PubMed ID: 29881274 [TBL] [Abstract][Full Text] [Related]
3. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach. Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280 [TBL] [Abstract][Full Text] [Related]
4. Formulation and Evaluation of Anisamide-Targeted Amphiphilic Cyclodextrin Nanoparticles To Promote Therapeutic Gene Silencing in a 3D Prostate Cancer Bone Metastases Model. Evans JC; Malhotra M; Fitzgerald KA; Guo J; Cronin MF; Curtin CM; O'Brien FJ; Darcy R; O'Driscoll CM Mol Pharm; 2017 Jan; 14(1):42-52. PubMed ID: 28043128 [TBL] [Abstract][Full Text] [Related]
5. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of siRNA/anti-cancer drug delivery system for non-melanoma skin cancer. Part I: Development and gene silencing of JAK1siRNA/5-FU loaded liposome nanocomplexes. Aslan M; Ozturk S; Shahbazi R; Bozdemir Ö; Dilara Zeybek N; Vargel İ; Eroğlu İ; Ulubayram K Eur J Pharm Biopharm; 2024 Oct; 203():114432. PubMed ID: 39097115 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Nishimura M; Jung EJ; Shah MY; Lu C; Spizzo R; Shimizu M; Han HD; Ivan C; Rossi S; Zhang X; Nicoloso MS; Wu SY; Almeida MI; Bottsford-Miller J; Pecot CV; Zand B; Matsuo K; Shahzad MM; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Calin GA Cancer Discov; 2013 Nov; 3(11):1302-15. PubMed ID: 24002999 [TBL] [Abstract][Full Text] [Related]
8. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance. Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340 [TBL] [Abstract][Full Text] [Related]
9. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery. Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773 [TBL] [Abstract][Full Text] [Related]
10. EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells. Cho MC; Cho SY; Yoon CY; Lee SB; Kwak C; Kim HH; Jeong H PLoS One; 2015; 10(7):e0130975. PubMed ID: 26177500 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous Delivery of Electrostatically Complexed Multiple Gene-Targeting siRNAs and an Anticancer Drug for Synergistically Enhanced Treatment of Prostate Cancer. Choi E; Yoo W; Park JH; Kim S Mol Pharm; 2018 Sep; 15(9):3777-3785. PubMed ID: 30028622 [TBL] [Abstract][Full Text] [Related]
12. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells. Lee J; Kim JS; Cho HI; Jo SR; Jang YK Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001 [TBL] [Abstract][Full Text] [Related]
13. JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway. Kim MS; Cho HI; Yoon HJ; Ahn YH; Park EJ; Jin YH; Jang YK Sci Rep; 2018 Apr; 8(1):6611. PubMed ID: 29700375 [TBL] [Abstract][Full Text] [Related]
14. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847 [TBL] [Abstract][Full Text] [Related]
15. Sustained small interfering RNA delivery by mesoporous silicon particles. Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760 [TBL] [Abstract][Full Text] [Related]
16. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781 [TBL] [Abstract][Full Text] [Related]
17. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280 [TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect of Qilan Capsules on the expressions of vasculogenic mimicry-related proteins in prostate cancer]. Yu XJ; Li JJ; Yang F; Dong L; Wu TL; Chang DG Zhonghua Nan Ke Xue; 2018 Jun; 24(6):533-539. PubMed ID: 30173460 [TBL] [Abstract][Full Text] [Related]
19. Development and characterization of an improved formulation of cholesteryl oleate-loaded cationic solid-lipid nanoparticles as an efficient non-viral gene delivery system. Limeres MJ; Suñé-Pou M; Prieto-Sánchez S; Moreno-Castro C; Nusblat AD; Hernández-Munain C; Castro GR; Suñé C; Suñé-Negre JM; Cuestas ML Colloids Surf B Biointerfaces; 2019 Dec; 184():110533. PubMed ID: 31593829 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]